Rystiggo Rozanolixizumab Injection

1. Indications and Usage
Generalized Myasthenia Gravis (gMG):
Treatment of adult patients who are anti-acetylcholine receptor (AChR) antibody-positive or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive.
2. Dosage and Administration
Route of Administration:
For Subcutaneous Infusion ONLY. Must be administered using an infusion pump.
Recommended Dosage:
Treatment consists of one cycle of weekly infusions for 6 weeks.
Weight-Based Dosing:
<50 kg: 420 mg once weekly for 6 weeks.
50–<100 kg: 560 mg once weekly for 6 weeks.
≥100 kg: 840 mg once weekly for 6 weeks.
Critical Administration Instructions:
Infusion Rate: Maximum infusion rate of 20 mL/hour.
Re-administration: The safety of subsequent cycles initiated within 63 days of the previous cycle start date has not been determined.
Setting: To be administered by a healthcare provider or under supervision.
3. Mechanism of Action
FcRn Antagonism:
Rozanolixizumab is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn).
IgG Degradation:
Normally, FcRn protects IgG from degradation and recycles it back into circulation. By blocking this interaction, Rozanolixizumab diverts pathogenic IgG antibodies (such as anti-AChR and anti-MuSK) to the lysosomal degradation pathway.
Therapeutic Result: This leads to a rapid and sustained reduction in serum total IgG and pathogenic autoantibody levels, alleviating neuromuscular symptoms.
4. Safety and Warnings
Infusion-Related Reactions:
Reactions may occur, including headache, pyrexia, and nausea. Monitor during infusion.
Increased Risk of Infection:
By lowering IgG levels, the drug may compromise the immune system.
Action: Defer treatment in patients with active infection. Assess vaccination status prior to starting a new cycle.
Aseptic Meningitis:
Cases of aseptic meningitis have been reported. If suspected, evaluate and treat appropriately.
Contraindications:
History of hypersensitivity to rozanolixizumab or any of its excipients.
5.Adverse Reactions and Clinical Research
Most Common Adverse Reactions:
Headache (48.4%), diarrhea, pyrexia, nausea, arthralgia, upper respiratory tract infection.
Clinical Research Highlights:
Efficacy: In the pivotal Phase 3 study (MycarinG), treatment with Rozanolixizumab resulted in a statistically significant improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at Day 43 compared to placebo.
IgG Reduction: The drug induced a rapid reduction in serum IgG, with maximum reductions observed around Day 10, and levels returning to baseline approximately 8 weeks after discontinuation.
6.Drug Interactions
Live Vaccines:
Avoid administration of live vaccines while IgG levels are suppressed.
Immunosuppressants:
No specific interactions identified, but caution is advised with concomitant immunosuppressive therapies due to additive infection risk.
7.Pharmaceutical Information
Chemical Composition:
Active Ingredient: Rozanolixizumab-noli.
Appearance: Clear, colorless to slightly yellow solution.
Packaging: Single-dose vial (280 mg/2 mL).
Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake.